Trial title not recorded
Short Bowel Syndrome
Enrolment: 8 · Results not recorded
Loading the evidence…
Hormone · Glucagon-like peptide 2 receptor agonist. h[Gly2]GLP-2 is the DPP-4-resistant analogue marketed as teduglutide (ATC A16AX08); ChEMBL holds no separate entry for the unbranded [Gly2]GLP-2 designation.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Short Bowel Syndrome
Enrolment: 8 · Results not recorded
Short Bowel Syndrome
Enrolment: 25 · Results not recorded
Short Bowel Syndrome
Enrolment: 10 · Results not recorded
Postoperative Fistula
Enrolment: 6 · Results not recorded
Hyperlipidaemias
Enrolment: 15 · Results not recorded
Short Bowel Syndrome
Enrolment: 65 · Results not recorded
Short Bowel Syndrome
Enrolment: 250 · Results not recorded
Short Bowel Syndrome · Intestinal Failure
Enrolment: 40 · Results not recorded
Short Bowel Syndrome
Enrolment: 1 · Results not recorded
Short Bowel Syndrome
Enrolment: 50 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Chronic cisplatin-induced colonic mucosal and enteric nervous system injury, cisplatin 4 mg/kg intraperitoneally twice weekly for 4 weeks with subcutaneous saline to limit nephrotoxicity
[Gly2]GLP-2 co-administration prevented the cisplatin-induced loss of total myenteric neurons, nNOS-immunoreactive neurons and SOX-10-immunoreactive glia and normalised IL-1beta and IL-10. Protection was partial, since weight loss, reduced mucosal area and PAS staining, reduced GFAP and S100beta an…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.